COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.

Pub Date : 2022-12-01 DOI:10.1358/dot.2022.58.12.3455368
Ioan-Alexandru Chirap-Mitulschi, Constantin Ghimus, Andreea Raluca Chirap-Mitulschi, Sabina Antonela Antoniu, Raluca Dragomir
{"title":"COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.","authors":"Ioan-Alexandru Chirap-Mitulschi,&nbsp;Constantin Ghimus,&nbsp;Andreea Raluca Chirap-Mitulschi,&nbsp;Sabina Antonela Antoniu,&nbsp;Raluca Dragomir","doi":"10.1358/dot.2022.58.12.3455368","DOIUrl":null,"url":null,"abstract":"<p><p>The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.</p>","PeriodicalId":72848,"journal":{"name":"","volume":"58 12","pages":"605-620"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dot.2022.58.12.3455368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受疾病改善治疗的多发性硬化症患者的COVID-19疫苗接种:务实问题
自2019年以来,SARS-COV-2大流行一直是一个全球公共卫生问题,报告病例超过4亿例,死亡600万人,并造成重大经济和社会损失。多发性硬化症(MS)等慢性疾病患者的重叠SARS-CoV-2感染会导致管理问题,特别是在接受疾病缓解疗法治疗的患者中。调查COVID-19疫苗接种有效性的研究表明,疫苗接种后免疫反应的变异性取决于患者的背景治疗,需要特别注意抗cd20治疗。本文对MS患者接受疾病改善治疗的COVID-19疫苗接种效果的现有数据进行了总结和批判性评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1